Hikma Pharmaceuticals PLC (LON: HIK)
London
· Delayed Price · Currency is GBP · Price in GBp
2,110.00
+26.00 (1.25%)
Jan 21, 2025, 4:58 PM BST
Hikma Pharmaceuticals Revenue
Hikma Pharmaceuticals had revenue of $1.57B USD in the half year ending June 30, 2024, with 29.35% growth. This brings the company's revenue in the last twelve months to $3.02B, up 10.47% year-over-year. In the year 2023, Hikma Pharmaceuticals had annual revenue of $2.88B with 14.22% growth.
Revenue (ttm)
$3.02B
Revenue Growth
+10.47%
P/S Ratio
1.95
Revenue / Employee
$331.54K
Employees
9,100
Market Cap
4.68B GBP
Revenue Chart
* This company reports financials in USD.
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2023 | 2.88B | 358.00M | 14.22% |
Dec 31, 2022 | 2.52B | -36.00M | -1.41% |
Dec 31, 2021 | 2.55B | 212.00M | 9.06% |
Dec 31, 2020 | 2.34B | 134.00M | 6.07% |
Dec 31, 2019 | 2.21B | 137.00M | 6.62% |
Dec 31, 2018 | Pro | Pro | Pro |
Dec 31, 2017 | Pro | Pro | Pro |
Dec 31, 2016 | Pro | Pro | Pro |
Dec 31, 2015 | Pro | Pro | Pro |
Dec 31, 2014 | Pro | Pro | Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
AstraZeneca | 38.20B |
GSK plc | 31.31B |
Haleon | 11.24B |
Smith & Nephew | 4.46B |
ConvaTec Group | 1.74B |
HUTCHMED (China) | 483.31M |
Oxford Nanopore Technologies | 167.75M |
Indivior | 881.89M |
Hikma Pharmaceuticals News
- 7 days ago - Hikma announces exclusive commercial partnership with Emergent BioSolutions for KLOXXADO® (naloxone HCl) nasal spray 8 mg - Benzinga
- 7 days ago - Hikma announces exclusive commercial partnership with Emergent BioSolutions for KLOXXADO® (naloxone HCl) nasal spray 8 mg - PRNewsWire
- 5 months ago - Jazz And Hikma Accused Of Delaying Sleep Disorder Generic Drug To Maintain High Prices - Benzinga
- 5 months ago - Hikma Pharmaceuticals participates in naloxone training event with U.S. Congressman Buddy Carter ahead of National Fentanyl Awareness and Prevention Day - PRNewsWire
- 5 months ago - KLOXXADO® 8mg Naloxone Nasal Spray Shelf-Life Extended from 24 months to 36 months - Benzinga
- 5 months ago - KLOXXADO® 8mg Naloxone Nasal Spray Shelf-Life Extended from 24 months to 36 months - PRNewsWire
- 5 months ago - Hikma Pharmaceuticals PLC (HKMPF) (H1 2024) Earnings Call Transcript Highlights: Strong Revenue ... - GuruFocus
- 5 months ago - Hikma Pharmaceuticals PLC (HKMPF) Q2 2024 Earnings Call Transcript - Seeking Alpha